{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:19:50Z","timestamp":1768011590076,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11255-022-03104-9","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T09:02:35Z","timestamp":1642237355000},"page":"533-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of the causes of BCG refractory in patients treated with intracavitary BCG as secondary treatment in superficial bladder tumors with transurethral resection"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-2015","authenticated-orcid":false,"given":"Enis Mert","family":"Yorulmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-9322","authenticated-orcid":false,"given":"Y\u00fcksel","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-6676","authenticated-orcid":false,"given":"Osman","family":"K\u00f6se","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-3476","authenticated-orcid":false,"given":"Yi\u011fit","family":"Ak\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-1249","authenticated-orcid":false,"given":"Sacit Nuri","family":"G\u00f6rgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-139X","authenticated-orcid":false,"given":"Serkan","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"issue":"6","key":"3104_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3104_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.eururo.2013.10.001","volume":"66","author":"S Chavan","year":"2014","unstructured":"Chavan S, Bray F, Lortet-Tieulent J et al (2014) International variations in bladder cancer incidence and mortality. Eur Urol 66(1):59\u201373","journal-title":"Eur Urol"},{"issue":"2","key":"3104_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234\u2013241","journal-title":"Eur Urol"},{"issue":"5","key":"3104_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bju.13102","volume":"116","author":"S Baltaci","year":"2015","unstructured":"Baltaci S, Bozlu M et al (2015) Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin. BJU Int 116(5):721\u2013726","journal-title":"BJU Int"},{"issue":"2","key":"3104_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","volume":"54","author":"M Babjuk","year":"2008","unstructured":"Babjuk M, Oosterlinck W, Sylvester R et al (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54(2):303\u2013314","journal-title":"Eur Urol"},{"key":"3104_CR6","first-page":"363","volume":"22","author":"W Catalona","year":"1990","unstructured":"Catalona W, Ratliff T (1990) Bacillus Calmette-Gu\u00e9rin and superficial bladder cancer. Clinical experience and mechanism of action. Surg Ann 22:363\u2013378","journal-title":"Surg Ann"},{"issue":"6","key":"3104_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6):1216\u20131223","journal-title":"Urology"},{"issue":"6","key":"3104_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1046\/j.1464-410X.2002.02692.x","volume":"89","author":"A Kolodziej","year":"2002","unstructured":"Kolodziej A, Dembowski J, Zdrojowy R et al (2002) Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Gu\u00e9rin therapy: preliminary results. BJU Int 89(6):620\u2013622","journal-title":"BJU Int"},{"issue":"16","key":"3104_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, B\u00f6hle A et al (2016) Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 34(16):1935","journal-title":"J Clin Oncol"},{"issue":"3","key":"3104_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, Van Der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013477","journal-title":"Eur Urol"},{"issue":"3","key":"3104_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"M Shelley","year":"2001","unstructured":"Shelley M, Kynaston H, Court J et al (2001) A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88(3):209\u2013216","journal-title":"BJU Int"},{"issue":"4","key":"3104_CR12","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates M, Matoso A, Choi W et al (2020) Adaptive immune resistance to intravesical BCG in non\u2013muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin Cancer Res 26(4):882\u2013891","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3104_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00345-018-2397-1","volume":"37","author":"M Ferro","year":"2019","unstructured":"Ferro M, Vartolomei MD, Russo GI et al (2019) An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol 37(3):507\u2013514","journal-title":"World J Urol"},{"issue":"3","key":"3104_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2174\/1871530318666180131094733","volume":"18","author":"MD Borges","year":"2018","unstructured":"Borges MD, Franca EL, Fujimori M et al (2018) Relationship between proinflammatory cytokines\/chemokines and adipokines in serum of young adults with obesity. Endocr Metab Immune Disord Drug Targets 18(3):260\u2013267","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"3104_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2018.01.039","volume":"480","author":"Y Lin","year":"2018","unstructured":"Lin Y, Wang Y, Wu Q et al (2018) Association between obesity and bladder cancer recurrence: A meta-analysis. Clin Chim Acta 480:41\u201346","journal-title":"Clin Chim Acta"},{"issue":"11","key":"3104_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1442-2042.2011.02845.x","volume":"18","author":"EC Hwang","year":"2011","unstructured":"Hwang EC, Kim YJ, Hwang IS et al (2011) Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 18(11):769\u2013776","journal-title":"Int J Urol"},{"key":"3104_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.urolonc.2020.02.016","volume":"38","author":"M Ferro","year":"2020","unstructured":"Ferro M, Katalin MO, Buonerba C et al (2020) Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Gu\u00e9rin after transurethral resection of the bladder tumor. Urol Oncol 38:459","journal-title":"Urol Oncol"},{"key":"3104_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000589","author":"F Dal Moro","year":"2015","unstructured":"Dal Moro F, Bovo A, Crestani A et al (2015) Effect of hypertension on outcomes of high-risk patients after BCG-treated bladder cancer: a single-institution long follow-up cohort study. Medicine (Baltimore). https:\/\/doi.org\/10.1097\/MD.0000000000000589","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"3104_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1464-410X.2007.06873.x","volume":"100","author":"CH Chen","year":"2007","unstructured":"Chen CH, Shun CT, Huang KH et al (2007) Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 100(2):281\u2013286","journal-title":"BJU Int"},{"issue":"6","key":"3104_CR20","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.eururo.2012.08.057","volume":"62","author":"M Rink","year":"2012","unstructured":"Rink M, Xylinas E, Babjuk M et al (2012) Smoking reduces the efficacy of intravesical bacillus Calmette-Gu\u00e9rin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol 62(6):1204\u20131206","journal-title":"Eur Urol"},{"issue":"5","key":"3104_CR21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","volume":"53","author":"J Fernandez-Gomez","year":"2008","unstructured":"Fernandez-Gomez J, Solsona E, Unda M et al (2008) Prognostic factors in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53(5):992\u20131002","journal-title":"Eur Urol"},{"issue":"5","key":"3104_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bju.12844","volume":"116","author":"L Lima","year":"2015","unstructured":"Lima L, Oliveira D, Ferreira JA et al (2015) The role of functional polymorphisms in immune response genes as biomarkers of bacille C almette-G u\u00e9rin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. BJU Int 116(5):753\u2013763","journal-title":"BJU Int"},{"issue":"7","key":"3104_CR23","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1464-410X.2011.10462.x","volume":"109","author":"R Segal","year":"2012","unstructured":"Segal R, Yafi FA, Brimo F et al (2012) Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 109(7):1026\u20131030","journal-title":"BJU Int"},{"issue":"3","key":"3104_CR24","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1007\/s12032-011-9999-4","volume":"29","author":"I Vukomanovic","year":"2012","unstructured":"Vukomanovic I, Colovic V, Soldatovic I et al (2012) Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer. Med Oncol 29(3):1916\u20131920","journal-title":"Med Oncol"},{"issue":"1","key":"3104_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cncr.22756","volume":"110","author":"AM Kamat","year":"2007","unstructured":"Kamat AM, Dinney CP, Gee JR et al (2007) Micropapillary bladder cancer: a review of the University of Texas MD Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62\u201367","journal-title":"Cancer"},{"issue":"1","key":"3104_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","volume":"190","author":"A Sengiku","year":"2013","unstructured":"Sengiku A, Ito M, Miyazaki Y et al (2013) A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol 190(1):50\u201354","journal-title":"J Urol"},{"issue":"3","key":"3104_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","volume":"198","author":"BE Boehm","year":"2017","unstructured":"Boehm BE, Cornell JE, Wang H et al (2017) Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol 198(3):503\u2013510","journal-title":"J Urol"},{"issue":"6","key":"3104_CR28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S0022-5347(17)39120-6","volume":"142","author":"AH M\u2019Liss","year":"1989","unstructured":"M\u2019Liss AH, Catalona WJ, Ritchey JK et al (1989) Choice of an optimal diluent for intravesical bacillus Calmette-Guerin administration. J Urol 142(6):1438\u20131441","journal-title":"J Urol"},{"issue":"5","key":"3104_CR29","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.31557\/APJCP.2019.20.5.1389","volume":"20","author":"T Nagai","year":"2019","unstructured":"Nagai T, Okamura T, Tanaka Y et al (2019) Evaluation of the dwell-time and dose difference in intravesical bacillus Calmette-Gu\u00e8rin therapy. Asian Pac J Cancer Prevent APJCP 20(5):1389","journal-title":"Asian Pac J Cancer Prevent APJCP"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03104-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03104-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03104-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T13:28:35Z","timestamp":1644499715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03104-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["3104"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03104-9","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"7 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was carried out in the urology clinic of \u0130zmir Katip \u00c7elebi University Atat\u00fcrk Training and Research Hospital with the approval of the Local Ethics Committee (25.07.2019\/Decision No: 78).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects for participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"At the ethics committee meeting dated 14.02.2019, the requested corrections were made by the researchers and found appropriate, and it was unanimously decided by the members of the ethics committee who attended the meeting that there was no ethical or scientific objection to the study in the centers specified in the application file.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Decision"}}]}}